|
|
|
Main conference:
Day 1
3 Sep 8am - 5:30pm
Day 2
4 Sep 8am - 5:30pm
Pre conference Masterclasses:
2 Sep: 8am - 5.30pm
Masterclass A:
Gaining regulatory approval for therapeutic monoclonal antibody for the US and EU markets
Manufacturing and scale-up issues in monoclonal antibody production
Post conference Masterclass:
5 Sep: 8am - 5.30pm
Immunogenicity assessment of therapeutic antibodies: Strategies and regulatory environment
› Conference Programme
› Add this to my calendar
|
|
We invite registered delegates to submit their posters for review. The best poster will be selected based on novelty, applicability and data clarity. The winner will stand to win the Asia Antibody Congress poster award and cash prizes.
|
|
|
|
|
Press and Media
Join us at Asia Antibody Congress 2008 for months of highly targeted exposure. Capitalise on this ideal platform to market your publication and form strategic relationships through networking at Asia Antibody Congress 2008!!
-
Brand your publication with an event that the industry believes in
-
Fully capitalise on our integrated marketing campaign
-
Increased customer contact and business opportunities
-
Wider exposure to International organisations
-
A unique opportunity to give clients “hands on” experience with your products / services
-
Gain exclusive interviews with the region’s movers and shakers
-
Avail yourself of invaluable editorial & feature content at the conference
For more information on how your title can be profiled as the industry's leading publication, please contact:
Lynn Chew
Marketing Manager
Email: lynn.chew@terrapinn.com
Tel: +65 6322 2729
Fax: +65 6226 3264
General Biologic is information, research, and advisory firm focused on China's pharmaceutical, biotechnology and healthcare industries. Based in Shanghai, GB helps companies and investors understand and act on opportunities in China. GB is the publisher of China Pharmaceutical & Biotechnology Monthly, industry reports, databases, and audio interviews with leaders in China's healthcare industry.
GB provides management consulting and transaction services to clients in aspects of solving difficult strategic and capital allocation issues. The main focus areas of GB’s consulting services for new-entries investors in China include market research; strategy development; valuation and due diligence; partner screening and management. GB’s strong local networks are critical to accessing quality investment and licensing opportunities. We provide unparalleled access in main areas like providing investment opportunities to private equity and venture capital clients and evaluating technologies for licensing.
|
|
|
|
Nils Lonberg
SVP & Scientific Director
Medarex, USA
Ya Jun Guo
Director
Shanghai Cell Engineering & Antibody Centre, China
Patrick Baeuerle
Chief Scientific Officer
Micromet, Germany
Rob Crombie
COO & VP of Business Development
Arana Therapeutics, Australia
Clive Wood
Executive VP & Chief Scientific Officer
Dyax, USA
Michael Buschle
President, Biologics
Glenmark Pharmaceuticals, India
Dianwu Ju
CEO
MediPharma Biotech, China
Masamichi Koike
President & CEO
BioWa, Kyowa Hakko, Japan
Armin Weidemann
Director, R&D
Morphosys, Germany
|
sponsorship opportunities
From the moment you confirm your involvement in a Terrapinn event, we will provide you with outstanding marketing opportunities, with a targeted campaign that will culminate in face-to-face meetings with customers and prospects.
| |
Target your market
For details contact Colin Zheng on 65 6322 2763 or send an email
|
|
|
|
|
|
|
|
|
|
|
